

Baymedix® FP512 prepolymer for hydrophilic foams

Baymedix® FP aliphatic prepolymers offering unique features to drive innovation and differentiation of hydrophilic polyurethane foams in advanced wound care applications and beyond



Baymedix® FP512

Baymedix® FP512 aliphatic isocyanate prepolymer enables a more sustainable production of hydrophilic foams. The lower water content of the foam production process reduces energy cost and allows the efficient manufacturing of combination products (foam & backing film).

PROPERTY	BAYMEDIX® FP512
NCO content	5.5 – 7.5%
Viscosity at 23°C	4,000 - 10,000 mPa·s

Hydrophilic foams based on **Baymedix® FP512** show excellent mechanical characteristics combined with capabilities to optimize moisture management in modern wound dressings or wound prevention dressings.

Key features of foams based on Baymedix® FP512


- · Excellent wet strength
- · Excellent retention
- · High absorption
- Compatible with common sterilization methods
- · Durable white (non-yellowing)

Properties of foams based on Baymedix® FP512

PROPERTY	BAYMEDIX® FP FOAM
Foam density (g/l)	80~100
Absorption* (g/g)	max. 1,800%
MVTR* (g/(day · m²))	> 3,000
Retention (6 kg, 20 s)	up to 50%
Swelling in saline solution (vol%)	~100


^{*}according to DIN EN 13726-1 Part 3.2/3.3

Wet elongation at break (%)*



*according to DIN EN ISO 527

Typical design of modern wound dressing



The manner in which you use our products, technical assistance and information (whether verbal, written or by way of production evaluations), including any suggested formulations and recommendations, are beyond our control. Therefore, it is imperative that you test our products to determine suitability for your processing and intended uses. Your analysis must at least include testing to determine suitability from a technical, health, safety, and environmental and regulatory standpoint. Such testing has not necessarily been done by Covestro, and Covestro has not obtained any approvals or licenses for a particular use or application of the product, unless explicitly stated otherwise. [EMEA only: If the intended use of the product is for the manufacture of a pharmaceutical/ medicinal product, medical device¹ or of pre-cursor products for medical devices or for other specifically regulated applications which leads or may lead to a regulatory obligation of Covestro Covestro must explicitly agree to such application before the sale]. Any samples provided by Covestro are for testing purposes only and not for commercial use. Unless we otherwise agree in writing, all products are sold strictly pursuant to the terms of our standard conditions of sale which are available upon request. All information, including technical assistance is given without warranty or guarantee and is subject to change without notice. It is expressly understood and agreed by you that you assume and hereby expressly release and indemnify us and hold us harmless from all liability, in tort, contract or otherwise, incurred in connection with the use of our products, technical assistance. and information. Any statement or recommendation not contained herein is unauthorized and shall not bind us. Nothing herein shall be construed as a recommendation to use any product in conflict with any claim of any patent relative to any material or its use. No license is implied or in fact granted under the claims of any patent. These values are typical values only. Unless explicitly agreed in written form, they do not constitute a binding material specification or warranted values ¹Please see the "Guidance on Use of Covestro Products in a Medical Application" document.

Edition: 2025



Covestro Deutschland AG Kaiser-Wilhelm-Allee 60 51373 Leverkusen Germany

solutions.covestro.com